Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 Clinical Trial Optional)

The Translational Research in Maternal and Pediatric Pharmacology and Therapeutics program is a federal funding opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services. This initiative reflects NIH’s long-standing commitment to advancing biomedical research that improves health outcomes for vulnerable populations, particularly pregnant and lactating women, fetuses, neonates, and children. The program is structured as an R21 exploratory/developmental grant mechanism, which is intended to support early-stage, high-impact research projects that may generate preliminary data and innovative approaches for future large-scale studies. The primary purpose of this funding opportunity is to support translational and clinical research that advances precision medicine for maternal and pediatric populations. Specifically, the program aims to foster the development of novel tools, models, and technologies that can directly impact clinical care. It also seeks to deepen scientific understanding of drug action mechanisms, including how physiological changes during pregnancy and early development influence pharmacokinetics and pharmacodynamics. Another key objective is to promote the discovery and development of new therapeutics, as well as the optimization or repurposing of existing drugs, to ensure safer and more effective treatment options for these populations. Funding under this program supports a wide range of research activities, including laboratory-based translational studies, clinical investigations, and interdisciplinary collaborations. While specific award amounts are not provided in the summary, the R21 mechanism typically supports short-term projects focused on innovation rather than extensive clinical trials, though clinical trials are allowed under this opportunity. Funds may be used for personnel, research supplies, data collection, and other allowable research-related expenses consistent with NIH policies. There is no cost-sharing or matching requirement, which lowers the financial barrier for applicants and encourages broad participation across sectors. Eligibility for this opportunity is intentionally broad to support diverse research contributions. Eligible applicants include higher education institutions, nonprofits with or without 501(c)(3) status, for-profit organizations, small businesses, tribal governments and organizations, and various government entities at the state, local, and federal levels. Additional eligible entities include minority-serving institutions such as Historically Black Colleges and Universities, Hispanic-serving institutions, and tribal colleges, as well as foreign organizations and regional entities. This inclusive eligibility framework is designed to encourage participation from a wide array of research institutions and communities. The application process requires submission through standard NIH and Grants.gov systems, including registration in required federal systems. Applicants must prepare a research proposal that aligns with the program’s objectives, including detailed plans for study design, methodology, and anticipated impact. Applications are evaluated based on NIH peer review criteria, including significance, innovation, approach, investigator qualifications, and research environment. Additional considerations may include the potential for clinical impact and alignment with program priorities. The timeline for this opportunity includes an original posting date of November 18, 2024, with updates as recent as June 5, 2026. The current application deadline is July 6, 2026. The opportunity is not explicitly stated as recurring, though NIH program announcements often follow multi-year cycles. Applicants are encouraged to review the full announcement for detailed submission instructions and contact NIH Grants Information via email for assistance. The program ultimately aims to accelerate scientific discovery and improve therapeutic outcomes for maternal and pediatric populations through targeted, innovative research.